| 吕 蒙,王 昂,王 杰,鄢 文,尤长宣.早期非小细胞肺癌患者血清巨噬细胞抑制因子-1、趋化素与临床病理特征及预后的关系[J].现代生物医学进展英文版,2019,19(21):4103-4107. |
| 早期非小细胞肺癌患者血清巨噬细胞抑制因子-1、趋化素与临床病理特征及预后的关系 |
| Relationship between Serum Macrophage Inhibitor-1, Chemokine and Clinicopathological Features and Prognosis in Patients with Early Non-small Cell Lung Cancer |
| Received:April 06, 2019 Revised:April 30, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.21.023 |
| 中文关键词: 非小细胞肺癌 巨噬细胞抑制因子-1 趋化素 病理特征 预后 |
| 英文关键词: Non-small cell lung cancer Macrophage inhibitor-1 Chemerin Pathological characteristics Prognosis |
| 基金项目:广东省科技计划项目（2017B090901067） |
| Author Name | Affiliation | E-mail | | LV Meng | Department of Oncology, Huiqiao Medical Center, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510000, China | quanli2019@126.com | | WANG Ang | First Ward of Oncology, Second People's Hospital of Guangdong Province, Guangzhou, Guangdong, 510000, China | | | WANG Jie | Department of Radiotherapy, Second People's Hospital of Guangdong Province, Guangzhou, Guangdong, 510000, China | | | YAN Wen | First Ward of Oncology, Second People's Hospital of Guangdong Province, Guangzhou, Guangdong, 510000, China | | | YOU Chang-xuan | Department of Oncology, Huiqiao Medical Center, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510000, China | |
|
| Hits: 812 |
| Download times: 582 |
| 中文摘要: |
| 摘要 目的：探讨早期非小细胞肺癌（NSCLC）患者血清巨噬细胞抑制因子-1（MIC-1）、趋化素（chemerin）水平与临床病理特征及预后的关系。方法：选择72例NSCLC患者（NSCLC组）、53例肺良性疾病患者（良性组）、50例体检健康人群（对照组），分别检测血清MIC-1、chemerin水平，分析血清MIC-1、chemerin水平与NSCLC患者临床病理参数的关系。Kaplan-Meier法分析不同血清MIC-1、chemerin水平NSCLC患者生存时间的差异，COX比例风险回归分析血清MIC-1、chemerin水平与NSCLC患者预后的关系。结果：NSCLC组患者血清MIC-1、chemerin水平高于良性组和对照组（P<0.05）。血清MIC-1水平与NSCLC患者年龄、目前吸烟、肿瘤直径、TNM分期、分化程度、复发或转移、生存状态有关（P<0.05），chemerin水平与NSCLC患者目前吸烟、TNM分期、复发或转移、生存状态有关（P<0.05）。高MIC-1水平患者生存率低于低MIC-1水平患者（P<0.05），高chemerin水平患者生存率低于低chemerin水平患者（P<0.05）。COX比例风险回归分析结果显示：血清MIC-1、chemerin、TNM分期与NSCLC不良预后独立相关。结论：血清MIC-1、chemerin水平与NSCLC患者部分临床病理参数和预后相关，可作为早期NSCLC患者预后预测的潜在指标。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum level of macrophage inhibitory factor-1 (MIC-1) and chemerin and clinicopathological features and prognosis in patients with early non-small cell lung cancer (NSCLC). Methods: 72 patients with NSCLC (NSCLC group), 53 patients with benign pulmonary diseases (benign group) and 50 healthy people (control group) were selected. Serum MIC-1 and chemerin levels were detected respectively. The relationship between serum MIC-1 and chemerin levels and clinicopathological parameters of NSCLC patients was analyzed. The survival time of NSCLC patients with different serum levels of MIC-1 and Chemerin was analyzed by Kaplan-Meier method. The relationship between serum levels of MIC-1 and chemerin and the prognosis of NSCLC patients was analyzed by COX proportional risk regression. Results: The serum MIC-1 and chemerin levels in NSCLC group were higher than those in benign group (P<0.05). Serum MIC-1 level was correlated with age, current smoking, tumor diameter, TNM stage, differentiation degree, recurrence or metastasis, survival status of NSCLC patients (P<0.05), and chemerin level was correlated with current smoking, TNM stage, recurrence or metastasis and survival status of NSCLC patients (P<0.05). The survival rate of patients with high MIC-1 level was lower than that of patients with low MIC-1 level (P<0.05), and survival rate of patients with high chemerin level was lower than that of patients with low chemerin level (P<0.05). COX proportional risk regression analysis showed that serum MIC-1, chemerin and TNM stage levels were independently associated with poor prognosis of NSCLC. Conclusion: Serum MIC-1 and chemerin levels are correlated with some clinicopathological parameters and prognosis of NSCLC patients, and they can be used as potential prognostic indicators for early NSCLC patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
